ZENECA CASODEX FOR ADVANCED PROSTATE CANCER RECEIVES ACCELERATED APPROVAL FROM FDA; AGENCY AWAITS COMPLETION OF EULEXIN COMPARISON FOR FULL APPROVAL
Zeneca's anti-androgen Casodex (bicalutamide) for use in combination with a luteinizing-hormone- releasing hormone analog in treatment of advanced prostate cancer was given accelerated approval by FDA Oct. 4. Submitted in September 1994, NDA 20-498 was reviewed in just over one year.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth